| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
OF-Deg-Lin does not have a defined pharmacological target; it is a formulation component. As an ionizable cationic lipid, it carries a positive charge in acidic environments (such as within endosomes), enhancing its interaction with negatively charged nucleic acids (mRNA, siRNA) and facilitating encapsulation. At physiological pH, it is neutrally charged, which reduces toxicity and prolongs circulation. The lipid is designed to be degradable, which helps minimize toxicity by allowing clearance after drug delivery. The primary mechanism of action is to facilitate the delivery of nucleic acids into target cells via LNP-mediated endocytosis and endosomal escape.
|
|---|---|
| ln Vitro |
In vitro, OF-Deg-Lin has been used in the generation of LNPs for the delivery of mRNA in cell culture. LNPs formulated with OF-Deg-Lin demonstrate efficient cellular uptake and transfection in various cell lines, including immune cells and hepatocytes. The ionizable nature of OF-Deg-Lin promotes endosomal escape, allowing the release of mRNA into the cytoplasm where it can be translated into the encoded protein. The degradable ester linkages in the lipid structure enhance biodegradability, potentially improving the safety profile of the LNPs. OF-Deg-Lin is used in the research and development of LNP-based mRNA vaccines and gene therapies.
|
| ln Vivo |
In vivo, OF-Deg-Lin is used to formulate LNPs that deliver mRNA and other nucleic acid therapeutics in animal models. LNPs formulated with OF-Deg-Lin show favorable biodistribution and pharmacokinetic properties, enabling efficient protein expression in target tissues such as the liver and spleen after intravenous administration. The degradable nature of OF-Deg-Lin may reduce the risk of lipid accumulation and chronic toxicity compared to non-degradable ionizable lipids. OF-Deg-Lin is a useful ionizable lipid for LNP-based vaccine and therapeutic development.
|
| Enzyme Assay |
For LNP formulation, OF-Deg-Lin is typically combined with helper lipids (e.g., DSPC, cholesterol, and PEG-lipid) in organic solvent (ethanol) at defined molar ratios (e.g., OF-Deg-Lin : cholesterol : DSPC : PEG-lipid = 50:38.5:10:1.5). The lipid mixture is mixed with an aqueous solution containing mRNA at a controlled flow rate using a microfluidic device, resulting in spontaneous LNP formation. The resulting LNPs are dialyzed against PBS to remove ethanol and concentrated by ultrafiltration. Particle size (typically 60-120 nm), polydispersity index, and encapsulation efficiency are characterized.
|
| Cell Assay |
For in vitro transfection assays, cells are seeded in 96-well plates and treated with LNPs containing mRNA encoding a reporter protein (e.g., luciferase or GFP). After 24-48 hours, reporter expression is quantified by bioluminescence (luciferase) or fluorescence microscopy/flow cytometry (GFP). Cytotoxicity is assessed by MTT assay.
|
| Animal Protocol |
For in vivo studies, OF-Deg-Lin-based LNPs are formulated to encapsulate mRNA (e.g., luciferase or a therapeutic protein), diluted in PBS or sucrose buffer, and administered to rodents via intravenous injection at doses of 0.1-5 mg/kg (based on mRNA content). Protein expression is measured by bioluminescence imaging (IVIS) or by tissue collection and assay for protein concentration (ELISA). Tissue distribution is assessed by quantifying mRNA content in organs (liver, spleen, lungs) by qPCR.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for OF-Deg-Lin as a free lipid are not available, as it is always formulated into LNPs. The molecular weight of OF-Deg-Lin is 1482.28, and the molecular formula is C92H160N4O10. It is an ionizable aminolipid that appears as an oil at room temperature. The degradable ester linkages in the lipid structure contribute to its biodegradability and clearance. The compound should be stored at -20degC to prevent degradation.
|
| Toxicity/Toxicokinetics |
Toxicological data for OF-Deg-Lin alone are limited, but as an ionizable lipid, it is expected to have an acceptable safety profile when used in LNP formulations at appropriate doses. LNP administration may cause transient elevation of liver enzymes (ALT/AST) and pro-inflammatory cytokines, which are typically dose-dependent and reversible. Comprehensive toxicity studies are formulation-dependent.
|
| References | |
| Additional Infomation |
OF-Deg-Lin is a research-grade compound and is not approved for clinical use. It is an ionizable amino lipid used exclusively for LNP formulation in drug delivery research. The degradable nature of the lipid is designed to improve the safety profile of LNPs by enabling clearance after drug delivery. OF-Deg-Lin is primarily used in the development of mRNA vaccines and gene therapies. The CAS number is 1853202-95-5. Store as an oil at -20degC in a sealed, airtight container under an inert atmosphere to prevent oxidation and degradation.
|
| Molecular Formula |
C92H160N4O10
|
|---|---|
| Molecular Weight |
1482.28
|
| Exact Mass |
1481.213
|
| CAS # |
1853202-95-5
|
| PubChem CID |
118631062
|
| Appearance |
Colorless to light yellow ointment
|
| LogP |
27.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
82
|
| Heavy Atom Count |
106
|
| Complexity |
2040
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC
|
| InChi Key |
HAZAXVJMCWCIDS-RGLFHLPNSA-N
|
| InChi Code |
InChI=1S/C92H160N4O10/c1-5-9-13-17-21-25-29-33-37-41-45-49-53-57-61-71-87(97)103-81-77-95(78-82-104-88(98)72-62-58-54-50-46-42-38-34-30-26-22-18-14-10-6-2)75-67-65-69-85-91(101)94-86(92(102)93-85)70-66-68-76-96(79-83-105-89(99)73-63-59-55-51-47-43-39-35-31-27-23-19-15-11-7-3)80-84-106-90(100)74-64-60-56-52-48-44-40-36-32-28-24-20-16-12-8-4/h21-28,33-40,85-86H,5-20,29-32,41-84H2,1-4H3,(H,93,102)(H,94,101)/b25-21-,26-22-,27-23-,28-24-,37-33-,38-34-,39-35-,40-36-
|
| Chemical Name |
2-[4-[5-[4-[bis[2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxyethyl]amino]butyl]-3,6-dioxopiperazin-2-yl]butyl-[2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxyethyl]amino]ethyl (9Z,12Z)-octadeca-9,12-dienoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6746 mL | 3.3732 mL | 6.7464 mL | |
| 5 mM | 0.1349 mL | 0.6746 mL | 1.3493 mL | |
| 10 mM | 0.0675 mL | 0.3373 mL | 0.6746 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
